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combined stroke and death rate.
Results: In total 269 patients had complete data and were included
in the analysis.The demographic and clinical data were similar in the
groups The 30-day combined stroke and death rate did not differ
signiﬁcantly between the groups; 0% (0/12) in the group treated 0e
2 days, versus 3.9% (3/76), 2.9% (2/68), and 5.3% (6/113) for the
patients treated at 3e7 days, 8e14 days and 15e180 days
respectively (p ¼ 0.759). The 30-day stroke and death rate in the
secondary analysis were also similar between groups; 3.4% (3/88),
2.9% (2/68), 6.3% (3/48), and 4.6% (3/65) respectively, (p¼ 0.813).
Conclusion: In this national registry study, limited by small
numbers, patients that underwent urgent CAS after onset of a
neurologic event had no additional risk of suffering from a peri-
operative complication.Lessons from 500 Adverse Event Reports on SFA Stents from
MAUDE Database-need for Action by ESVS?
R. Gambhir
King’s College Hospital, London, UK
Introduction: When a Boeing aircraft develops a problem at New
York, within the next 24 hrs the whole Boeing ﬂeet, the world over,
gets an alert with initial defect report, cause and a ﬁx. On the
other hand when the trigger mechanism of delivery system of an
SFA stent fails in a London Hospital, nothing similar happens. FDA
mandates the manufacturers to report all adverse events within 30
days on the MUADE database. An analysis of 500 adverse event
reports on SFA stents reveals lessons for the vascular societies and
calls for uniﬁed action for the sake of patient safety.
Methods: MAUDE database was searched for all adverse event
reports on SFA stents from 01/04/2012 to 31/03/2014. Each report
lists the event description, the date, patient injury, intervention if
required and the manufacturer’s narrative.
Results: 500 SFA stent adverse reports were recorded and ana-
lysed. All known manufacturers were listed. Adverse reports from
2 stent manufacturers were signiﬁcantly more than the others. A
similar deployment failure was reported for over 1 year by one
manufacturer. More than 1/3rd of the reported cases had either a
failure in deployment of the stent or retrieval of the standard
delivery system (sds). In another 1/3rd the stent was damaged
after deployment-twisted, torqued, fractured, or occluded. In the
remaining 1/3rd there were multitudes of problems from breakage
of sds components and their retention within the patient to
dislodgment.
Adverse patient effects included Acute Limb ischemia, limb loss
and death. Majority required endovascular intervention, failing
which an open procedure was performed in 20% of patients.
Analysis of manufacturer’s narrative rarely revealed no attrib-
utable cause, the malfunction, mal-deployment was labeled as
procedure related and not device related. The manufacturer’s
narrative often stated that the device met pre-release speciﬁca-
tions and no manufacturing defect could be identiﬁed.
Conclusion: A review of adverse event reports form manufac-
turer’s clearly indicates that the adverse event was procedure
related and probably due to the operator not exercising due care
or not following the IFU. There is a need for the societies to take
a lead in user adverse event reporting, analysis and communi-
cating these to the centre’s on a deﬁnitive time scale in a more
open and uniﬁed manner to prevent patient harm and improve
outcomes.Impact of Early Pelvic and Lower Limbs Reperfusion and
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Introduction: Spinal cord ischemia (SCI) is a devastating compli-
cation following thoracoabdominal aortic aneurysm (TAAA)
endovascular repair. In an attempt to reduce its occurrence, we
have modiﬁed our implantation protocol in January 2010 by
withdrawing all large sheaths from the iliac arteries as soon as
possible during the procedure. In addition, we have also modiﬁed
our perioperative protocol (aggressive blood and platelet trans-
fusion, median arterial pressure monitoring >80 mmHg, and sys-
tematic cerebrospinal ﬂuid drainage except for type 4 TAAA).
Methods: Between October 2004 and December 2013, we have
performed 204 TAAA endovascular repairs with custom made
devices manufactured with branches and fenestrations to perfuse
the visceral vessels. Data from all patients were prospectively
collected in an electronic database. We compared the early out-
comes of patients treated before (group 1, 43 patients) and after
(group 2, 161 patients) modiﬁcation of our implantation and
perioperative protocols.
Results: Group 1 and 2 patients had similar comorbidities (median
age at repair 70.9 years [65.2e77]), aneurysm characteristics
(median diameter 58.5 mm [53e65]), and length of procedure
(median 190 min [150e240]). The in-hospital mortality rate was
11.6% in group 1 vs. 5.6% in group 2 respectively (RR ¼ 0.481
[0.17e1.36]; p ¼ 0.09). The spinal cord ischemia rate was 14% vs.
1.2% (RR ¼ 1.148 [1.016e1.296]; p ¼ 0.001) respectively. If we
exclude Type 4 TAAA from this analysis, the spinal cord ischemia
rate was 25% (6/24 patients) in group 1 vs. 2.1% (2/95 patients) in
group 2 (RR ¼ 1.306 [1.034e1.648]; p < 0.001) respectively.
Conclusion: Early restoration of arterial ﬂow to the pelvis and
lower limbs and aggressive perioperative management signiﬁ-
cantly reduces SCI following TAAA endovascular repair. With this
modiﬁed approach, extensive TAAA endovascular repairs are
associated with low rates of SCI.Endovascular Management of Rupture in Acute Type B Aortic
Dissections
E. Faure, L. Canaud, J.P. Becquemin, P. Alric
Department of Thoracic and Vascular Surgery; University Hospital, Montpellier,
France
Introduction: Reports of thoracic endovascular aortic repair
(TEVAR) for complicated acute type B dissection bring together a
large range of clinical presentations.With a 50% of 30-day mortality
rate whenmanaged with open surgery, rupture is themost dramatic
complication of acute type B dissections. We investigated the out-
comes of TEVAR for acute type B dissection complicated by rupture
(R-ABD) to assess the results of this particularly critical subgroup.
Methods: A review of consecutive TEVAR for R-ABD in two tertiary
centers was performed using prospectively maintained database.
Results: Between 2000 and 2014, 24 patients (mean age 68 years;
14 males) underwent TEVAR for R-ABD. Sixteen (67%) were in
shock (Systolic blood pressure <80 mmHg) before surgery and 20
required chest drainage for hemothorax. Proximal entry tear was
in zone 2 in 7 (29%) and 3 in 17 (71%). Five patients required
coverage of the left subclavian artery for adequate proximal
